Litcius/Paper detail

Structure-guided design of a methyltransferase-like 3 (METTL3) proteolysis targeting chimera (PROTAC) incorporating an indole–nicotinamide chemotype

Annabelle C. Weldert, Ariane F. Frey, Mackenzie W. Krone, Franziska Krähe, Hannah Kuhn, Christian Kersten, Fabian Barthels

2025RSC Medicinal Chemistry10 citationsDOIOpen Access PDF

Abstract

A level reduction in cancer cells than its non-PRTOAC parent compounds. By incorporating the indole-nicotinamide chemotype as the METTL3-binding recruiter, this PROTAC is structurally distinct from recently published METTL3 PROTACs, expanding the design options for future METTL3 degrader development.

Topics & Concepts

ProteolysisChimera (genetics)Indole testChemotypeComputational biologyChemistryBiologyStereochemistryBiochemistryEnzymeGeneChromatographyEssential oilProtein Degradation and InhibitorsCancer-related gene regulationUbiquitin and proteasome pathways
Structure-guided design of a methyltransferase-like 3 (METTL3) proteolysis targeting chimera (PROTAC) incorporating an indole–nicotinamide chemotype | Litcius